| Literature DB >> 32714945 |
Moritz Blum1, Djawid Hashemi1,2, Laura Astrid Motzkus1, Marthe Neye1, Aleksandar Dordevic1, Victoria Zieschang3, Seyedeh Mahsa Zamani3, Tomas Lapinskas3,4, Kilian Runte5,6, Marcus Kelm5,6, Titus Kühne2,5,6, Elvis Tahirovic1,2, Frank Edelmann1,2, Burkert Pieske1,2,3, Hans-Dirk Düngen1,2, Sebastian Kelle1,2,3.
Abstract
Background: Fast strain-encoded cardiac magnetic resonance imaging (cMRI, fast-SENC) is a novel technology potentially improving characterization of heart failure (HF) patients by quantifying cardiac strain. We sought to describe the impact of isometric handgrip exercise (HG) on cardiac strain assessed by fast-SENC in HF patients and controls.Entities:
Keywords: cardiac magnetic resonance imaging; fast SENC; heart failure; isometric handgrip; strain
Year: 2020 PMID: 32714945 PMCID: PMC7344153 DOI: 10.3389/fcvm.2020.00111
Source DB: PubMed Journal: Front Cardiovasc Med ISSN: 2297-055X
Figure 1Fast strain-encoded cardiac magnetic resonance imaging. (A) 62 year-old male with heart failure with reduced ejection fraction; (B) 62 year-old male without heart disease; all subjects were at physical rest during image acquisition; all images were acquired at end-systole; global longitudinal strain is derived from short axis views at apical, mid and basal level; global circumferential strain is derived from two-, three-, and for-chamber views.
Baseline characteristics.
| Female Sex–no. (%) | 9 (47.4) | 8 (47.1) | 6 (33.3) | 3 (16.7) | 0.176 |
| Age–years | 61.5 ± 8.1 | 77.9 ± 8.0 | 67.9 ± 9.2 | 65.4 ± 10.5 | <0.001 |
| BMI–kg/m2 | 25.1 ± 3.2 | 27.6 ± 3.8 | 27.3 ± 4.6 | 28.1 ± 3.8 | 0.104 |
| CAD–no. (%) | 0 (0.0) | 11 (64.7) | 15 (83.3) | 13 (72.2) | <0.001 |
| Hypertension–no. (%) | 7 (36.8) | 15 (88.2) | 14 (77.8) | 15 (83.3) | 0.002 |
| Previous MI–no. (%) | 0 (0.0) | 7 (41.2) | 14 (77.8) | 8 (44.4) | <0.001 |
| Previous PCI–no. (%) | 0 (0.0) | 9 (52.9) | 14 (77.8) | 12 (66.7) | <0.001 |
| Diabetes mellitus–no. (%) | 2 (10.5) | 5 (29.4) | 3 (16.7) | 5 (27.8) | 0.441 |
| LBBB on ECG–no. (%) | 0 (0.0) | 0 (0.0) | 1 (5.6) | 2 (11.1) | 0.281 |
| Ever Smoked–no. (%) | 4 (21.1) | 8 (47.1) | 15 (83.3) | 13 (72.2) | 0.001 |
| Packyears–years | 2.0 ± 4.3 | 3.9 ± 6.8 | 29.8 ± 32.1 | 34.7 ± 52.7 | 0.003 |
| NYHA Class II–no. (%) | 0 (0.0) | 10 (58.8) | 15 (83.3) | 15(72.2) | <0.001 |
| III–no. (%) | 0 (0.0) | 7 (41.2) | 3 (16.7) | 3 (27.8) | |
| Leg Edema–no. (%) | 3 (15.8) | 12 (70.1) | 14 (77.8) | 12 (66.7) | <0.001 |
| 6 min walk distance–m | 523.0 ± 118.6 | 344.4 ± 118.3 | 411.7 ± 86.0 | 417.4 ± 122.8 | <0.001 |
| MLHFQ QOL Score | 4.7 ± 5.7 | 31.0 ± 23.1 | 25.2 ± 21.0 | 30.6 ± 25.8 | <0.001 |
| Beta-Blocker–no. (%) | 6 (31.6) | 11 (64.7) | 14 (77.8) | 17 (94.4) | <0.001 |
| ACE-Inhibitor - no. (%) | 2 (10.5) | 3 (17.6) | 6 (33.3) | 10 (55.6) | 0.015 |
| ARB–no. (%) | 4 (21.1) | 12 (70.6) | 7 (38.9) | 8 (44.4) | 0.027 |
| MRA–no. (%) | 0 (0.0) | 3 (17.6) | 4 (22.2) | 11 (61.1) | <0.001 |
| ARNI–no. (%) | 0 (0.0) | 1 (5.9) | 0 (0.0) | 4 (22.2) | 0.026 |
| Statin–no. (%) | 2 (10.5) | 9 (52.9) | 15 (83.3) | 11 (61.1) | <0.001 |
| Loop Diuretic–no. (%) | 0 (0.0) | 3 (17.6) | 6 (33.3) | 7 (38.9) | 0.02 |
| HCT–no. (%) | 4 (21.1) | 4 (23.5) | 2 (11.1) | 1 (5.6) | 0.401 |
| Hb–g/dl | 14.0 ± 1.1 | 13.0 ± 1.3 | 13.7 ± 1.1 | 14.9 ± 1.2 | <0.001 |
| RBC–/pl | 4.7 ± 0.4 | 4.4 ± 0.5 | 4.5 ± 0.5 | 4.9 ± 0.5 | 0.007 |
| WBC–/nl | 6.1 ± 1.5 | 7.2 ± 2.4 | 8.5 ± 2.4 | 8.3 ± 2.3 | 0.003 |
| Platelets–/nl | 263.4 ± 65.9 | 265.8 ± 74.9 | 266.9 ± 74.0 | 209.7 ± 48.2 | 0.03 |
| Hematocrit | 0.40 ± 0.03 | 0.38 ± 0.03 | 0.41 ± 0.03 | 0.43 ± 0.04 | 0.001 |
| Cholesterol–mg/dl | 203.5 ± 33.5 | 172.5 ± 35.4 | 154.2 ± 44.3 | 156.1 ± 37.3 | <0.001 |
| LDL–mg/dl | 133.0 ± 39.4 | 106.8 ± 29.5 | 92.2 ± 39.2 | 87.8 ± 30.4 | 0.001 |
| HDL–mg/dl | 66.5 ± 25.3 | 52.6 ± 12.8 | 49.4 ± 14.7 | 51.6 ± 18.3 | 0.029 |
| Triglycerides–mg/dl | 130.4 ± 79.6 | 129.7 ± 50.2 | 137.9 ± 81.1 | 173.3 ± 153.1 | 0.508 |
| HbA1c –% | 5.4 ± 0.5 | 5.9 ± 0.8 | 5.9 ± 0.7 | 5.8 ± 0.82 | 0.215 |
| NTproBNP–ng/l | 88.7 ± 61.1 | 459.1 ± 470.3 | 543.7 ± 385.5 | 2413.1 ± 3417.3 | 0.001 |
| logNTproBNP–ng/l | 4.26 ± 0.73 | 5.72 ± 1.13 | 6.06 ± 0.73 | 7.01 ± 1.20 | <0.001 |
| Hs TroponinT– ng/l | 7.1 ± 3.4 | 19.9 ± 18.2 | 18.2 ± 19.67 | 19.4 ± 12.4 | 0.029 |
| CRP–mg/l | 1.3 ± 1.4 | 2.9 ± 2.7 | 3.1 ± 4.2 | 1.1 ± 0.7 | 0.029 |
| LVEF –% | 61.6 ± 5.4 | 61.6 ± 6.1 | 45.1 ± 2.7 | 33.5 ± 4.9 | <0.001 |
| LV EDV–ml | 148.0 ± 34.5 | 130.3 ± 35.5 | 175.9 ± 28.8 | 261.8 ± 59.4 | <0.001 |
| LV ESV–ml | 56.1 ± 18.4 | 50.9 ± 18.5 | 96.8 ± 17.7 | 175.6 ± 48.5 | <0.001 |
| LV SV–ml | 90.1 ± 17.4 | 79.3 ± 20.1 | 79.1 ± 12.7 | 86.2 ± 16.6 | 0.144 |
ARB, angiotensin receptor blocker; ARNI, angiotensin receptor blocker–neprilysin inhibitor; BP, blood pressure EDV, end-diastolic volume; EF, ejection fraction; ECG, electrocardiogram; ESV, end-systolic volume; GCS, global circumferential strain; GLS, global longitudinal strain; HF, heart failure; HFpEF, HF with preserved EF; HFmrEF, HF with mid-range EF; HFrEF, HF with reduced EF; LBBB, left bundle branch block; MI, myocardial infarction; MLHFQ, Minnesota living with heart failure questionnaire; MRA, mineralocorticoid receptor antagonist, PCI, percutaneous coronary intervention; QOL, quality of life; RBC, red blood cells; WBC, white blood cells.
Hemodynamic characteristics and strain at rest and during isometric exercise.
| Heart rate (/min) | Rest | 59.9 ± 8.5 | 63.6 ± 9.8 | 64.3 ± 7.1 | 65.2 ± 7.0 | 0.231 |
| HG | 69.4 ± 10.9 | 71.5 ± 10.6 | 71.7 ± 8.5 | 74.2 ± 8.1 | 0.514 | |
| % Change | +16.2 ± 11.8 | +12.9 ± 9.4 | +11.6 ± 7.1 | +14.3 ± 9.7 | 0.531 | |
| Systolic BP (mmHg) | Rest | 129.8 ± 14.9 | 126.5 ± 19.2 | 119.9 ± 17.8 | 118.6 ± 17.7 | 0.165 |
| HG | 163.2 ± 20.2 | 156.2 ± 18.8 | 147.8 ± 17.3 | 140.7 ± 22.8 | 0.006 | |
| % Change | +26.3 ± 13.5 | +24.8 ± 16.4 | +24.1 ± 10.6 | +18.9 ± 9.7 | 0.343 | |
| Diastolic BP (mmHg) | Rest | 70.5 ± 6.6 | 67.8 ± 9.7 | 67.9 ± 8.8 | 68.8 ± 8.6 | 0.757 |
| HG | 86.7 ± 8.6 | 84.7 ± 11.9 | 82.2 ± 8.3 | 82.7 ± 13.1 | 0.562 | |
| % Change | +23.3 ± 11.5 | +25.7 ± 13.7 | +22.1 ± 13.3 | +20.6 ± 14.7 | 0.714 | |
| Pulse pressure (mmHg) | Rest | 59.4 ± 13.4 | 58.8 ± 13.2 | 51.9 ± 12.6 | 49.7 ± 11.9 | 0.06 |
| HG | 76.5 ± 18.5 | 71.5 ± 11.4 | 65.6 ± 13.7 | 58.1 ± 13.9 | 0.002 | |
| % Change | +30.0 ± 22.2 | +24.9 ± 25.3 | +28.2 ± 18.1 | +17.3 ± 11.7 | 0.238 | |
| LV GLS | Rest | −20.1 ± 1.7 | −19.1 ± 1.2 | −16.0 ± 2.8 | −11.4 ± 4.0 | <0.001 |
| HG | −20.2 ± 1.5 | −19.0 ± 2.1 | −15.6 ± 2.6 | −11.0 ± 4.1 | <0.001 | |
| % Change | +1.2 ± 5.4 | −0.6 ± 8.3 | −1.7 ± 10.7 | −3.1 ± 19.4 | 0.746 | |
| LV GCS | Rest | −18.7 ± 2.4 | −16.9 ± 2.3 | −13.0 ± 3.5 | −11.2 ± 3.3 | <0.001 |
| HG | −18.4 ± 2.5 | −17.2 ± 2.0 | −13.1 ± 2.6 | −10.6 ± 2.8 | <0.001 | |
| % Change | −0.8 ± 11.0 | +3.1 ± 11.6 | 10.8 ± 48.6 | −2.4 ± 18.1 | 0.467 |
Difference between rest and HG significant (p < 0.05), assessed with paired t-test. BP, blood pressure; EF, ejection fraction; GCS, global circumferential strain; GLS, global longitudinal strain; HF, heart failure; HFpEF, HF with preserved EF; HFmrEF, HF with mid-range EF; HFrEF, HF with reduced EF, HG, isometric handgrip; LV, left ventricle.
Figure 2Hemodynamic measurements at rest and during isometric exercise (A) at rest and (B) during isometric exercise. Reported are p-values from analysis of variance. Asterisks indicate significant inter-group difference in Tukey's post-hoc test of analysis of variance (p < 0.05). BP, blood pressure; EF, ejection fraction; HF, heart failure; HFpEF, HF with preserved EF; HFmrEF, HF with mid-range EF; HFrEF, HF with reduced EF.
Figure 3Cardiac strain at rest and during isometric exercise (A) at rest and (B) during isometric exercise. Asterisks indicate significant inter-group difference in Tukey's post-hoc test of analysis of variance (p < 0.05). EF, ejection fraction; GCS, global circumferential strain; GLS, global longitudinal strain; HF, heart failure; HFpEF, HF with preserved EF; HFmrEF, HF with mid-range EF; HFrEF, HF with reduced EF; LV, left ventricle.
Figure 4Strain response to isometric exercise (A) LV GLS overall and in subgroups, (B) LV GCS overall and in subgroups. EF, ejection fraction; GCS, global circumferential strain; GLS, global longitudinal strain; HF, heart failure; HFpEF, HF with preserved EF; HFmrEF, HF with mid-range EF; HFrEF, HF with reduced EF; LV, left ventricle.
Categorization of change in strain during isometric exercise.
| LV GLS | Increase–no. (%) | 7 (36.8) | 6 (35.3) | 3 (16.7) | 4 (22.2) | 0.668 |
| No change–no. (%) | 7 (36.8) | 7 (41.2) | 9 (50.0) | 6 (33.3) | ||
| Decrease–no. (%) | 5 (26.3) | 4 (23.5) | 6 (33.3) | 8 (44.4) | ||
| LV GCS | Increase– no. (%) | 7 (36.8) | 9 (52.9) | 6 (33.3) | 7 (38.9) | 0.831 |
| No change– no. (%) | 4 (21.1) | 4 (23.5) | 3 (16.7) | 3 (16.7) | ||
| Decrease–no. (%) | 8 (42.1) | 4 (23.5) | 9 (50.0) | 8 (44.4) |
Increase: Δ LV GLS < −0.5; No change: −0.5 ≤ Δ LV GLS ≤ +0.5; Increase: Δ LV GLS > +0.5; Abbreviations: EF, ejection fraction; GCS, global circumferential strain; GLS, global longitudinal strain; HF, heart failure; HFpEF, HF with preserved EF; HFmrEF, HF with mid-range EF; HFrEF, HF with reduced EF; LV, left ventricle.
Change in strain during isometric exercise.
| % change | +1.2 ± 5.4 | −0.6 ± 8.3 | −1.7 ± 10.7 | −3.1 ± 19.4 | 0.746 |
| Absolute value of % change | 4.4 ± 3.2 | 5.9 ± 5.7 | 6.8 ± 8.3 | 14.1 ± 13.3 | 0.005 |
| % change | −0.8 ± 11.0 | +3.1 ± 11.6 | +10.8 ± 48.6 | −2.4 ± 18.1 | 0.467 |
| Absolute value of % change | 8.6 ± 6.6 | 9.8 ± 6.6 | 28.3 ± 40.4 | 14.7 ± 10.2 | 0.028 |
EF, ejection fraction; GCS, global circumferential strain; GLS, global longitudinal strain; HF, heart failure; HFpEF, HF with preserved EF; HFmrEF, HF with mid-range EF; HFrEF, HF with reduced EF, HG, isometric handgrip; LV, left ventricle.
Figure 5Association of absolute change in strain during isometric exercise and (A) LV EF at rest, (B) log NTproBNP, and (C) MLHQ quality of life score. Reported are Pearson's r coefficients. NTproBNP was transformed by the natural logarithm function. EF, ejection fraction; GLS, global longitudinal strain; LV, left ventricle; MLHQ, Minnesota living with heart failure questionnaire; NTproBNP, N-terminal pro-brain natriuretic peptide.